Tepotinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 237 publications

Risk of peripheral edema in cancer patients receiving MET inhibitors: a systematic review and meta-analysis.

Risk of peripheral edema in cancer patients receiving MET inhibitors: a systematic review and meta-analysis.

Journal: Journal of chemotherapy (Florence, Italy)

Published: May 03, 2026

Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.

Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.

Journal: Lung cancer management

Published: April 04, 2026

A novel c-Met inhibitor containing chiral pyrrolidine side chain and its application as anti-tumor agents.

A novel c-Met inhibitor containing chiral pyrrolidine side chain and its application as anti-tumor agents.

Journal: European journal of medicinal chemistry

Published: March 02, 2026

Large-scale transcriptomic data mining using explainable XGBoost and SHAP reveals shared biomarkers and molecular mechanisms between type-2 diabetes and triple-negative breast cancer for drug repurposing.

Large-scale transcriptomic data mining using explainable XGBoost and SHAP reveals shared biomarkers and molecular mechanisms between type-2 diabetes and triple-negative breast cancer for drug repurposing.

Journal: BioData mining

Published: February 21, 2026

Knockdown of FAXDC2 promotes cell proliferation, migration, invasion and EMT in HepG2 cells by upregulating c-Met and its phosphorylation.

Knockdown of FAXDC2 promotes cell proliferation, migration, invasion and EMT in HepG2 cells by upregulating c-Met and its phosphorylation.

Journal: Molecular biology reports

Published: February 11, 2026

A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.

A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.

Journal: Renal failure

Published: January 25, 2026

Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.

Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.

Journal: Journal of translational medicine

Published: January 19, 2026

Tepotinib Therapy for Advanced MET Exon 14 Skipping NSCLC With Non-Dialysis End-Stage Renal Disease: A Case Report.

Tepotinib Therapy for Advanced MET Exon 14 Skipping NSCLC With Non-Dialysis End-Stage Renal Disease: A Case Report.

Journal: Respirology case reports

Published: January 05, 2026

Reversal of Paraneoplastic Non-Bacterial Thrombotic Endocarditis with Heparin and Targeted Cancer Therapy: A Case Report.

Reversal of Paraneoplastic Non-Bacterial Thrombotic Endocarditis with Heparin and Targeted Cancer Therapy: A Case Report.

Journal: Reports (MDPI)

Published: December 31, 2025

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2025

Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.

Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.

Journal: Critical reviews in oncology/hematology

Published: December 08, 2025

Real-World Evidence for 10 Oncology Drugs Approved in the last 5 years: A Comprehensive Narrative Synthesis.

Real-World Evidence for 10 Oncology Drugs Approved in the last 5 years: A Comprehensive Narrative Synthesis.

Journal: Critical reviews in oncology/hematology

Published: December 08, 2025

Showing 1-12 of 237

Last Updated: 06/30/2026